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Albumin-coupled methotrexate (MTX-HSA) is a new
anti-arthritic drug which acts synergistically to MTX
C. Fiehn, U. Mu¨ller-Ladner1, S. Gay2, S. Krienke, S. Freudenberg-Konrad,
J. Funk, A. D. Ho, H. Sinn3 and A. Wunder3,4
Objective. To evaluate the anti-arthritic effects of the new inﬂammation-targeted drug MTX-HSA and to investigate whether
peripheral blood mononuclear cells (PBMC) are potential target cells for albumin-mediated drug delivery.
Methods. The murine model of collagen-induced arthritis (CIA) was used to measure the anti-arthritic effect of MTX, MTX-
HSA or a combination of both (n¼ 30 to 35 per group). In addition, the uptake of ﬂuorescence-labelled albumin (AFLc-HSA)
in PBMC of 14 patients with RA was measured by ﬂuorescence-activated cell sorting (FACS).
Results. In equivalent doses of 7.5mg/kg intravenously (IV) twice a week, MTX-HSA is signiﬁcantly (P<0.02) superior to
MTX in inhibiting the development of CIA and reducing the joint count as well as the number of affected paws. When given in
lower doses as combination therapy, both drugs act synergistically (P<0.03). A mean of 96, 72 and 64% of the CD14-, CD16-
and CD20-positive cells from peripheral blood of rheumatoid arthritis (RA) patients showed an uptake of albumin after
incubation with AFLc-HSA in vitro. This ﬁnding was not signiﬁcantly different in comparison to healthy controls. In contrast,
the number of CD3-positive cells taking up albumin is increased signiﬁcantly in RA patients in comparison to controls
(26.3 12.9% S.D. vs 11.6 7.3% S.D.; P¼ 0.005).
Conclusion. The data show that the effectiveness of MTX-HSA in CIA is superior to MTX and that both drugs act
synergistically. In addition, albumin appears to be taken up by peripheral blood cells, suggesting that they might be one of the
potential target cells of this novel anti-arthritic treatment approach.
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A predominant feature of synovitis in rheumatoid arthritis (RA)
is the development of a hypertrophic, oedematous and highly
vascularized so-called pannus-like tissue that progressively invades
and degrades adjacent cartilage and bone [1–4]. This tissue, which
originates from the synovial lining layer of affected joints, consists
of synovial ﬁbroblasts (SFs), synovial macrophages and various
inﬁltrating inﬂammatory cells such as activated T and B lympho-
cytes. The joint destruction is mediated by matrix-degrading
enzymes released predominantly by activated SFs similar to
mechanisms observed in malignant disease [5, 6]. Due to these
activated properties of cellular components, both RA and various
malignant diseases can be treated with antiproliferative drugs such
as methotrexate (MTX) [7, 8], which has evolved into the most
commonly used drug in the treatment of RA [9, 10].
On the other hand, at present progression of joint destruction
cannot be completely inhibited by MTX treatment in most RA
patients. One reason might be that large amounts of the
administered MTX are eliminated by the kidneys within a short
period of time, resulting in short plasma half-life of less than 24 h
and a low drug concentration in the affected joints. Although
increasing the dose of MTX frequently results in a higher
therapeutic efﬁcacy, it also leads to a higher risk of side-effects.
These side-effects limit the maximum dose that can be adminis-
tered [9, 10]. The disadvantageous pharmacokinetic properties of
MTX are therefore most likely to be the basis of numerous
unsatisfactory treatment results [11–13].
To overcome the lack of speciﬁcity with regard to the target
tissue and prolong the effective half-life, drugs can be covalently
coupled to suitable drug carriers such as macromolecular proteins.
These carriers should provide a high accumulation in the target
tissue with a prolonged drug exposure time combined with low
uptake rates in non-diseased tissue.
Recently we demonstrated that by covalent coupling of MTX to
the plasma protein albumin (MTX-HSA), a drug conjugate is
created that fulﬁls these requirements for enhanced and speciﬁc
delivery of drugs into target tissue in malignant diseases as well as
into synovial tissue in patients with RA: albumin conjugates were
taken up intracellularly and were metabolized lysosomally by cells
with a high protein and nitrogen demand such as tumour cells [14,
15] or SFs of RA patients [1–3, 5, 6, 16]. Furthermore, MTX-HSA
has a plasma half-life of about 15 days, which is equivalent to
HSA; it showed no immunogenicity and was well tolerated in a
clinical Phase I trial for cancer treatment [17]. At present, the
conjugate is under clinical investigation in Phase II clinical trials.
The potential use of albumin as a drug carrier in RA is favoured
by the facts that the permeability of the blood–joint barrier for
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albumin in inﬂamed joints is markedly increased [18] and patients
with active RA, similar to cachectic cancer patients [15], frequently
develop hypoalbuminaemia due to increased albumin turnover,
presumably caused by high consumption of albumin at sites of
inﬂammation [19–21]. In accordance with this, we showed that in
different animal models albumin conjugates accumulated in
tumours as well as in inﬂamed joints of arthritic mice [16].
Moreover, MTX-HSA is superior to MTX in the suppression of
tumour growth [14, 15] and development of arthritis [16] in rodent
models. Moreover, in a human SCID mouse model of RA, in
which synovial ﬁbroblasts of patients with RA are co-transplanted
with cartilage, we recently showed that the cartilage-invading
synovial ﬁbroblasts take up albumin conjugates intracellularly [16].
In this speciﬁc model, MTX and MTX-HSA both inhibited
cartilage invasion and degradation with comparable efﬁciency [22].
Therefore, albumin appears to be a suitable drug carrier not
only for tumour therapy but also for the treatment of RA, and the
covalent coupling of MTX to albumin might increase therapeutic
efﬁcacy and reduce the side-effects of MTX.
However, several questions regarding the application of MTX-
HSA in arthritis still need to be addressed: (1) do MTX and MTX-
HSA act synergistically in the prevention of arthritis as they do in
some experimental tumor models and (2) are SFs [16] the only
cellular target of MTX-HSA, or might mononuclear cells be
additional target cells for the treatment with albumin conjugates?
In the work presented here, we therefore show the effects of the
application of MTX-HSA alone or in combination with MTX in
the murine collagen-induced arthritis (CIA) model, and we analyse
the albumin uptake of peripheral blood mononuclear cells
(PBMC) from RA patients in vitro.
Patients and methods
Reagents
Human serum albumin (HSA) was purchased from Pharma
Dessau (Dessau, Germany). Diethylenetriaminepentaacetic acid
(DTPA), dimethylsulphoxide (DMSO), N,N0-dicyclohexylcarbo-
diimide (DCC), and N-hydroxysuccinimide (HSI) were provided
by Aldrich (Steinheim, Germany). For separation of the com-
pounds, ultraﬁltration units (exclusion size 30 kDa) fromMillipore
(Eschborn, Germany) were used. 5([4,6-Dichlorotriacin-2-yl]-
amino)-ﬂuorescein (AFLc), bovine type II collagen, anti-mouse-
IgG Fc-speciﬁc biotin conjugate and methotrexate (MTX)
were purchased from Sigma (Deisenhofen, Germany). Incomplete
Freund’s adjuvant andMycobacterium tuberculosis H 37 RA were
from Difco/Becton-Dickinson (Detroit, USA). Streptavidin–
horseradish peroxidase (HRP) complex was obtained from
Amersham Life Science (Freiburg, Germany). Ficoll was from
BiochromKG (Berlin, Germany). Anti-CD3 IgG1 kappa phycoer-
ythrin (PE) conjugated, anti-CD14 IgG2a kappa PE conjugated,
anti-CD16 IgG1 kappa PE conjugated and anti-CD20 IgG1
kappa PE conjugated were from DAKO (Hamburg, Germany).
Fluorescence labelling of human serum albumin with
aminoﬂuorescein (AFLc-HSA)
For the covalent coupling of AFLc to albumin in a 1:1 molar ratio,
4 g HSA (diluted in 20ml saline), 20ml 0.17M NaHCO3 and 15ml
methanol were combined. With continuous stirring 45mg AFLc,
diluted in 4ml DMSO, was added. After 1 h, 350ml H2O was
added, and the low-molecular-weight compounds were separated
by ultraﬁltration. This step was repeated ﬁve times. Finally, the
puriﬁed AFLc-HSA conjugate was diluted in sodium bicarbonate
buffer (0.17M, pH 8.4), and the concentration of AFLc was
determined by absorbance at 497 nm. Quality controls were carried
out by HPLC analysis. No polymer formation was observed
during the conjugation procedure. The HPLC proﬁle of AFLc-
HSA was consistent with the proﬁle of HSA.
Coupling of methotrexate to human serum albumin
(MTX-HSA)
MTX-HSA was prepared as described previously, using N,N0-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide
(HSI) for activation and linking MTX to HSA [24].
Collagen-induced arthritis (CIA)
All animal experiments were approved by the Animal Welfare
Committee according to the regulations of the German Federal
Government. Two hundred and eighty-three male DBA/1 mice,
7–8 weeks of age, were obtained from M&B (Ry, Denmark). The
mice were maintained in the central animal house at the University
of Heidelberg. CIA was induced according to the procedure des-
cribed by Wooley [25, 26]: Bovine type II collagen was dissolved
in 0.1M acetic acid at a concentration of 2mg/ml by stirring for
about 3 h at 4C. To prepare the adjuvant, 3mg heat-inactivated
Mycobacterium tuberculosis was added to 1ml incomplete
Freund’s adjuvant. Equal volumes of the collagen solution and
the adjuvant were emulsiﬁed at 4C. The mice were immunized by
three intradermal injections of the emulsion at the base of the tail
(50l each). Three weeks after the ﬁrst immunization, the
procedure was repeated. Within 2 weeks of the second immuniza-
tion, about 70% of the mice developed arthritis characterized by
erythema and swelling of the paws. In the majority of mice, the
disease progressed to two or more paws. The severity of arthritis
was graded on a score of 0–3 as described before [27, 28].
Anti-collagen II antibody ELISA
Serum was obtained from anaesthetized mice by intracardial
puncture at the end of the treatment period, which was 2 weeks
after the second immunization. The concentrations of antibodies
against bovine collagen II in the serum of DBA/1 mice were
measured by the enzyme-linked immunosorbent assay (ELISA)
technique as described in [27]. Brieﬂy, bovine collagen II was
coated to 96-well microtitre plates (7g/well) by incubation for
24 h at 4C. After washing with phosphate-buffered saline with
0.2M NaCl and Tween 20 (PNT buffer) and incubation with 1%
HSA in PNT buffer, the serum of CIA mice was added and
incubated for 18 h at 4C. As a standard, the serum of a CIAmouse
with a known concentration of anti-collagen antibody (courtesy of
A. M. Malfyt, Kennedy Institute of Rheumatology, London, UK)
was added in different concentrations. After an other washing step
1g/ml biotinylated Fc-speciﬁc anti-mouse IgG was incubated for
2 h at room temperature. Following a washing step with PNP
buffer the bound antibodies were detected by HRP-streptavidin
complex and o-phenylenediamine (OPD) and the blue colour
quantiﬁed at 450 nm in an ELISA-reader.
Treatment protocol in CIA
Toxicity studies were performed to evaluate the maximum
tolerated dose (MTD): when the drugs were applied to ﬁve
DBA/1 mice per group twice weekly, a MTD of 35mg/kg body
weight for MTX and 7.5mg/kg for MTX-HSA was calculated.
The difference in the MTD between MTX and MTX-HSA
is easily explained by the longer half-life of MTX-HSA which
is about 2 days in comparison to <12h for MTX, which results in
a higher exposure of the mice to MTX-HSA in comparison to
MTX when both drugs are given twice weekly.
To study the effect of MTX-HSA andMTX on the development
of CIA, 267 DBA/1 mice were distributed randomly among seven
groups. Two weeks after the ﬁrst immunization with collagen
(2 weeks before the onset of arthritis), treatment was started.
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The animals were treated twice weekly for 4 weeks, each mouse
receiving eight injections. One group received intraperitoneal
injections of saline (group 1, control, n¼ 63). The mice in the six
treatment groups (n¼ 30 to 36) were injected intraperitoneally with
MTX either 7.5 or 35mg/kg body weight, MTX-HSA either 1.6 or
7.5mg/kg or both drugs in combination either 3.75mg/kg MTX
plus 0.8mg/kg MTX-HSA or 17.5mg/kg MTX plus 3.75mg/kg
MTX-HSA (Fig. 1). The dosage of the drugs was chosen either to
obtain the maximal effect by using the maximum tolerated dose
(see above) or to obtain the maximal difference between the single
drugs in low concentrations and their combination in order to
prove the synergy between both drugs. The calculated dose of
MTX-HSA was based on the amount of MTX bound to albumin.
Therefore, mice which were treated with equivalent doses of either
MTX-HSA or MTX received the same molar amount of the MTX
component, but either covalently coupled or non-coupled to
albumin. After 4 weeks of treatment, all mice were sacriﬁced
according to the local animal welfare regulations, which constitute
that mice must not be affected by arthritis for longer than 2 weeks.
During the course of the experiment, the mice were inspected twice
weekly for arthritis, side-effects of treatment, and were weighed.
The percentages of mice affected by CIA in each animal group
were calculated. Statistical signiﬁcance was tested using the
Fortran subroutine Fytest.
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FIG. 1. Effect of different doses of MTX, MTX-HSA or a combination of both on the development of collagen-induced arthritis
(CIA) of mice. The percentages of arthritic mice in each treatment group are presented (¼ arthritis incidence). Treatment was started
2 weeks before the onset of the disease. The animals were treated for 4 weeks and received two intraperitoneal injections weekly. The
dosage of both drugs is calculated by the molecular amount of MTX which is given as a free drug (MTX) or covalently coupled to
albumin (MTX-HSA). MTX and MTX-HSA suppressed signiﬁcantly (P<0.001) the development of arthritis (lower row). 7.5 mg/kg
MTX-HSA (lower row) was signiﬁcantly (P<0.02) more effective in the suppression of the onset of arthritis than the equivalent dose
of MTX (upper row). At least a 5-fold higher dose of MTX was required to achieve the levels of suppression seen with MTX-HSA.
When both drugs were combined and given in 50% of the dose of the drugs alone, in the low-dose schedules (upper row) a
signiﬁcantly (P<0.03) reduced incidence of arthritis in comparison with treatment with a single drug was found. This difference was
also seen in higher dosages of the drugs (lower row), but here it did not reach statistical signiﬁcance.
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Fluorescence signal of peripheral blood mononuclear cell
populations after in vitro incubation with AFLc-HSA
Peripheral blood mononuclear cells (PBMC) were obtained by
Ficoll centrifugation of plasma from 14 RA patients and 11
healthy controls. All RA patients fulﬁlled the American College
of Rheumatology (ACR; formerly the American Rheumatism
Association) criteria for the diagnosis of RA [29] and written
consent was obtained according to the Declaration of Helsinki.
The study has been approved by the ethics committee of the
University of Heidelberg.
The characteristics of patients and healthy controls are
described in Table 1.
1 106 PBMC/ml in 24-well plates were incubated in the
presence of 50g/ml AFLc-HSA at 37C for 15–17 h.
Afterwards the cells were vigorously washed three times and PE-
labelled antibodies against CD3, CD14, CD16 and CD20 were
added and incubated on ice for 20min. After a further washing step
the PBMC were analysed by ﬂuorescence-activated cell sorting
(FACS) (Becton-Dickinson, Detroit, USA) for the AFLc-HSA
signal (FL1) and binding of the PE-labelled antibodies (FL2).
Results
Treatment results
Of the control animals, 68% developed arthritis during the course
of the study.
When low doses of the drugs were used (Fig. 1, upper row), the
incidence of arthritis in mice treated with 7.5mg/kg MTX or
1.6mg/kg MTX-HSA was 57%, which was not signiﬁcantly
different from the control group. However, when 50% of the
doses of each drug are given in combination (3.75mg/kg MTX
plus 0.8mg/kg MTX-HSA) a signiﬁcantly (P<0.03) lower inci-
dence of arthritis of 29% can be observed. Therefore, both drugs
act synergistically, as an only additive effect would result in
the same incidence of arthritis as 7.5mg/kg MTX or 1.6mg/kg
MTX-HSA alone.
When high doses of the drugs are given (Fig. 1, lower row)
MTX-HSA as well as MTX or the combination of both drugs
show a signiﬁcantly better reduction of incidence of arthritis (37, 28
and 18% respectively) in comparison to the control group
(P<0.001 each). Therefore, although the synergistic effect of
the combination of MTX-HSA and MTX in comparison to the
single drugs is still detectable in this high-dose setting, it fails to
reach signiﬁcance.
Remarkably, 7.5mg of MTX-HSA/kg was signiﬁcantly better
(P<0.02) than equivalent doses of MTX in inducing reduction in
the incidence of arthritis. Moreover, a high MTX-dose of 35mg
MTX/kg was required to obtain a reduction of incidence of
arthritis to 37%, which is closest to the incidence of arthritis of
28% obtained with 7.5mg MTX-HSA/kg.
Similar results were found when instead of incidence of arthritis,
the arthritis score or the number of affected paws of all mice
were analysed (Fig. 2). In the group of mice which received lower
doses of the drugs (7.5mg/kg MTX, 1.6mg/kg MTX-HSA or
3.75mg/kg MTX plus 0.8mg/kg MTX-HSA) an effect of the
combination of both drugs in the reduction of the arthritis score
(control 3.0 0.4 S.E.M. and 2.2 0.5, 2.7 0.6 and 1.0 0.3
respectively in the treatment groups) and on the reduction of
the number of affected paws (control: 1.2 0.1 S.E.M. and 0.9 0.2,
1.2 0.2 and 0.5 0.1 respectively in the treatment groups) could
be shown, which was statistically signiﬁcant (P<0.04 and P<0.05
respectively). In contrast, the arthritis scores and the number
of affected paws were signiﬁcantly (P<0.005 and P<0.007
respectively) reduced by the treatment with high doses of both
drugs or the combination of both (35mg/kg MTX, 7.5mg/kg
MTX-HSA and 17.5mg/kg MTX plus 3.75mg/kg MTX-HSA)
but no signiﬁcant synergistic effect of the combination of both
drugs was detectable. Remarkably, when only the mice which
developed arthritis were analysed no signiﬁcant difference was
found between the treatment groups, showing that once the
mice developed arthritis the treatment did not alter the course
of the disease.
Anti-collagen type II antibody concentrations in serum
While no anti-collagen type II antibodies were detectable in
the serum of naı¨ve DBA/1 mice, in almost all mice that received
immunization with intradermal collagen type II for the induction
of CIA, anti-collagen type II antibodies were detectable in the
serum in a range from 20 up to 1000g/ml (Fig. 3) at the end of
the treatment period. The concentrations of anti-collagen type II
antibodies were signiﬁcantly reduced by MTX, MTX-HSA or a
combination of both, when high doses of the drugs are used
(P<0.05; Fig. 3, left lower row) and a synergistic effect between
MTX-HSA and MTX could be observed when lower concentra-
tions of the drugs were used (Fig. 3, left upper row). Signiﬁcantly
higher concentrations of collagen type II antibodies could be found
in the mice which developed arthritis in comparison to the mice
not showing signs of arthritis (Fig. 3, right column).
FACS analysis of PBMC
PBMC from 14 patients with RA and 11 healthy individuals were
incubated with ﬂuorescence-coupled albumin (AFLc-HSA) and
afterwards AFLc-HSA uptake (FL1) in different cell populations
TABLE 1. Characteristics of patients and healthy controls
RA patients Healthy controls
n 14 11
Mean age (yr) 55.6 16.7 (S.D.) 39.9 11.6 (S.D.)
Female gender 8 (57%) 6 (55%)
Disease activity score (DAS28) [41] 3.2 1.9 (S.D.), range 0.8–6.0 –
C-reactive protein (CRP) in plasma (mg/l) 10.1 10.7 (S.D.), range 2.0–39.1 –
Years from disease onset 8.2 3.1 (S.D.), range: 1.8–22.0 –
Treatment regimen Pred. only, 3 –
Pred.þMTX, 2
Pred.þMTXþLEF, 2
Pred.þMTXþ SSZ, 1
Pred.þMTXþETA, 4
Pred.þMTXþ INF, 1
ETA, 1
Abbreviations: Pred., prednisone or prednisolone; MTX, methotrexate; LEF, leﬂunomide; SSZ, sulphasalazine; ETA, etanercept; INF, inﬂiximab.
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was analysed by FACS (Fig. 4). The absolute cell counts in the
peripheral blood of RA patients were 3.8/nl for CD3-positive cells,
1.4/nl for CD14-positive cells, 1.6/nl for CD16-positive cells and
1.6/nl for CD20-positive cells. Almost all CD14-positive cells
showed FL1 positivity after incubation with AFLc-HSA in vitro,
regardless of whether they were derived from patients with RA
(96.1 8.2% S.D.) or from healthy individuals (98.7 1.8% S.D.).
In the CD16-positive cell population, the percentage of cells with
FL1 positivity was 72.1 21.7% S.D. (RA) and 62.0 15.3% S.D.
(controls) and in the CD20-positive cell population 64.7 31.3%
S.D. and 53.4 20.5 S.D. respectively. Although the rate of FL1-
positive cells in the CD16- and CD20-positive populations was
higher in RA patients, this difference failed to reach statistical
signiﬁcance.
In contrast to the CD14-, CD16- and CD20-positive cell popula-
tions, in the CD3-positive population the rate of cells showing a
ﬂuorescence signal after incubation with ﬂuorescence-labelled
albumin was much lower. Only 26.3 12.9% S.D. of the CD3-
positive cells from patients with RA showed a ﬂuorescence signal
after incubation with AFLc-HSA. However, in comparison with
the healthy individuals, which have a rate of 11.7 7.2% S.D., this
is signiﬁcantly increased (P¼ 0.005). When we correlated
the results with clinical and laboratory data from the patients we
could not ﬁnd a signiﬁcant correlation between AFLc-HSA
ﬂuorescence in any of the cell populations and the parameters
sex, age, C-reactive protein (CRP) concentration in the serum,
disease activity score (DAS28), time since ﬁrst diagnosis of RA or
the actual medication. Moreover, the frequency of ﬂuorescence-
positive cells after AFLc-HSA incubation was not correlated
with the absolute count of the different cell populations in
the peripheral blood.
Discussion
Albumin is the largest transportable source of nitrogen and energy
in the body and can be used to carry drugs to cells with a high
nitrogen and energy demand such as the cells involved in the
synovial inﬂammation of RA [14–16, 30]. We have recently shown
thatMTX-HSA is more effective than equivalent concentrations of
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FIG. 2. Arthritis scores and number of affected paws of mice with CIA treated with different concentrations of MTX, MTX-HSA or
both. The arthritis score is calculated by a clinical score of 0–3 per paw (maximum score of 12 per mouse). In parallel to the effects of
the treatment on arthritis incidence (Fig. 1), MTX, MTX-HSA and a combination of both signiﬁcantly reduces the arthritis score and
the number of affected paws when given in high doses (lower row, P<0.007). Moreover, a signiﬁcant synergistic effect of MTX and
MTX-HSA on arthritis score (P<0.04) and the number of affected paws (P<0.05) is detectable when the drugs are given in lower
doses (upper row). However, when only the mice which developed arthritis were analysed, no signiﬁcant difference was found, which
shows that the treatment did not inﬂuence the severity of arthritis in mice once they did develop arthritis. Results are shown as
mean S.E.M.
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MTX in preventing CIA [16]. Remarkably, in these experiments a
high MTX dose of 35mg of MTX/kg twice weekly was required to
obtain a result comparable to 7.5mg of MTX-HSA/kg, showing
the superior effect of MTX-HSA in comparison to MTX.
In the data reported here we now show that when both drugs
were combined, a synergistic effect was observed. Small doses of
both drugs in combination were sufﬁcient to obtain effects which
resembled those which could be obtained when high doses of the
single drugs were applied. This result corresponds to the observa-
tion that in RA the combination of MTX with other disease-
modifying drugs (DMARDs) or cytokine inhibitors, which have
different cellular targets and modulate different pathophysiologi-
cal pathways, leads to synergistic effects in terms of increased
therapeutic efﬁcacy. In clinical settings this has been shown for the
combination of MTX with cyclosporin A [31], sulphasalazine and
hydroxychloroquine [32] and leﬂunomide [33] as well as the
combination of MTX with inhibitors of tumour necrosis factor-
(TNF-) [34, 35]. Although MTX-HSA most likely shares the
majority of modes of action with MTX, the two agents need to be
regarded as pharmacologically separate drugs as they have
different distributions in the body [16] and might therefore target
different cell populations. Moreover, while MTX is taken up
intracellularly by folate receptors [36, 37], albumin conjugates are
internalized into cells by endocytosis [38]. These different mecha-
nisms of cellular uptake might therefore result in a different pattern
of cells, which are susceptible to treatment with either MTX-HSA
or MTX. Therefore, our ﬁndings that MTX-HSA and MTX have
synergistic effects in the prevention of CIA might be due to the fact
that MTX-HSA and MTX complement each other in their anti-
inﬂammatory effect by targeting different cell populations. The
signiﬁcance of the synergistic effect of MTX and MTX-HSA is
supported by the fact that we have previously found similar
synergistic effects between MTX-HSA and MTX in the growth
retardation of Walker-256 carcinosarcoma in rats [23].
In human RA, the therapeutic effect of MTX can usually be
observed after a treatment period of at least 4 weeks. As a similar
effect can be expected in murine CIA, we started the treatment
of the mice with MTX, MTX-HSA or both before the onset of
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FIG. 3. Anti-collagen type II-antibodies in the serum of CIA mice treated with different doses of MTX-HSA, MTX or a combination
of both as determined by the ELISA-technique. The serum was sampled at the end of the treatment period. In parallel to the effects of
the treatment on arthritis incidence (Fig. 1), arthritis scores and the number of affected paws (Fig. 2) MTX, MTX-HSA and a
combination of both signiﬁcantly (P<0.05) reduces the concentrations of anti-collagen type II antibodies when given in high doses
(left bottom). A synergistic effect (P<0.03) between both drugs is detectable when given in lower doses (left top). Mice which
developed arthritis had signiﬁcantly higher concentrations of antibodies in comparison to mice which did not develop arthritis. This
was found regardless of whether the mice received MTX, MTX-HSA or a combination of both drugs in low doses (right top,
P<0.001) or high doses (right bottom, P<0.001). Results are shown as mean S.E.M.
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arthritis to evaluate the effect of the treatment on the course of
arthritis in the ﬁrst weeks after onset, which in CIA mice is the
most active period of arthritis. Moreover, local animal welfare
regulations did not permit the follow-up of CIA mice for longer
than 2 weeks after the onset of arthritis. Therefore, we focused on
the effect of the treatment on the incidence of the disease rather
than the reduction of established arthritis which would have
required a much longer and ethically non-permissible follow-up
period of the arthritic mice.
Murine albumin can be obtained in small quantities only, which
makes it difﬁcult to perform in vivo experiments. Therefore, in
the present study we used MTX-coupled human albumin (HSA)
to treat DBA/1 mice. As HSA is xenologous in mice, it has
the potential to be immunogenic. However, we have previously
shown that the distribution of rat and human albumin in rats is
not different. Moreover, in rats or nude mice, multiple injections
of various HSA–drug conjugates were well tolerated and the
animals did not show signs of allergy or anaphylaxis [14, 15, 39].
Therefore, as albumin is highly conserved in the evolution of
mammals and as rats and mice as rodents have many similarities,
we hypothesize that interspecies differences between mice and
rats in the distribution of human albumin can be neglected.
Moreover, as HSA is coupled to the immunosuppressive drug
MTX (MTX-HSA), the immunogenicity might be further reduced.
Little is known about the uptake of MTX by inﬂammatory
cells in human RA. However, it has been shown that polygluta-
mated MTX is found in leucocytes of patients with RA [40].
Knowledge of the cellular distribution of MTX-HSA in RA would
give more insight in the mechanisms of its effect and the reason
for the synergistic effect with MTX described above.
In previous studies we identiﬁed synovial ﬁbroblasts [16] as
potential target cells for albumin-mediated drug delivery in
arthritis. For this cell population, which is found in an activated
state in synovitis and which is involved in the key pathophysi-
ological processes of RA, we could show by confocal laser
scanning microscope that albumin is taken up intracellularly and
that it is metabolized in the lysosomal compartment of the cell. In
the work presented here, we chose to use the FACS technique to
study the uptake of ﬂuorescence-labelled albumin in cell popula-
tions of the peripheral blood of patients with RA and of healthy
individuals. In contrast to confocal microscopy, the FACS tech-
nique provides information about the frequency of cells which
take up albumin and, by double-staining with PE-labelled
antibodies speciﬁc for cell surface markers, it provides information
about the albumin uptake of different cell types without a previ-
ous separation step. However, although the cells were vigorously
washed to remove albumin, FACS staining, in contrast to confocal
microscopy, does not completely exclude binding of albumin to
the cell surface.
Using double-staining, monocytes and granulocytes in particu-
lar, but also B lymphocytes, stained by anti-CD14, anti-CD16
and anti-CD20 antibodies respectively showed a positive ﬂuores-
cence signal after incubation with AFLc-HSA (Fig. 4) indicating
the intracellular uptake of albumin. However, there was no
signiﬁcant difference in the frequency of ﬂuorescence-positive
cells between patients with RA and the control group, although
there was a trend towards a higher rate in granulocytes and
B lymphocytes from RA patients in comparison with the control
group. In T lymphocytes stained by anti-CD3 antibodies the
frequency of cells with positive ﬂuorescence as a surrogate marker
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FIG. 4. Percentage of positive ﬂuorescence signal of subpopulations of PBMC from patients with RA and healthy controls after
incubation with 50g/ml ﬂuorescence-labelled albumin (AFLc-HSA) in vitro. As the cells were vigorously washed after incubation, the
ﬂuorescence signal most likely represents intracellular uptake of the albumin by the cells. Monocytes, and to a lesser degree
granulocytes and B lymphocytes, show the highest percentage of albumin uptake in vitro. Although granulocytes and B lymphocytes
from RA patients showed a higher rate of albumin uptake in comparison to the control group, no statistical difference was reached.
In contrast, T lymphocytes had a generally lower rate of albumin uptake, but this was signiﬁcantly (P<0.003) increased in cells
derived from patients with RA. In the lower row representative pictures of the FACS analysis of different populations of PBMC after
incubation with AFLc-HSA are shown. Vertical bars represent the mean values.
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of albumin uptake was generally lower in comparison to the
other cell types (Fig. 4). However, in the T lymphocytes the
frequency of cells which showed ﬂuorescence after incubation with
AFLc-HSA was signiﬁcantly increased in cells from patients with
RA in comparison with the control group.
We therefore conclude that a number of blood-borne effector
cell populations of synovial inﬂammation such as monocytes,
granulocytes and B lymphocytes can take up albumin to a high rate
and therefore are targeted by a treatment with albumin–drug
conjugates. T lymphocytes comprise an additional cell popula-
tion which is attributed to have an important role in RA. It has
been shown that in peripheral blood and the synovial tissue of
patients with RA, T lymphocytes are found which have an
activated phenotype [41]. Our observation that T lymphocytes
from the peripheral blood of patients with RA take up albumin
in a signiﬁcantly higher frequency than those of healthy control
individuals shows that the albumin demand of this, most likely
activated T lymphocytes, is increased in RA. It therefore represents
an interesting target cell population for albumin–drug conjugates.
Further studies have to show whether the uptake of MTX-HSA
by PBMC is different from that of MTX and whether this might be
a cause of the synergism between the both drugs.
In conclusion, MTX-HSA acts synergistically with MTX to
prevent murine CIA. Therefore, the option of a combination
therapy of both drugs should be included in further clinical stud-
ies with MTX-HSA in RA.MTX-HSAmost likely exerts its effects
through accumulation of the drug in effector cell populations of
RA. In addition to synovial ﬁbroblasts, which we previously
identiﬁed as target cells for albumin-mediated drug delivery in RA,
monocytes, granulocytes and T and B lymphocytes, which all were
shown to play a signiﬁcant role in the pathophysiology of this
disease, might be further targets of this novel treatment approach.
In the work presented here we did not evaluate the effects of MTX-
HSA on synovial inﬂammation, cartilage damage or bone
erosions. However, in a recent work we found an inhibitory effect
of both MTX and MTX-HSA on synovial ﬁbroblast invasion and
destruction of cartilage in a human SCIDmouse model of RA [22].
Nevertheless, the potential differential effects of MTX and MTX-
HSA on joint inﬂammation and destruction remain to be
determined in further studies.
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